Live feed
·
INSIDERFilingvia Quantisnow
BioVie Inc. logo

BioVie (BIVI) CEO Do received 104,502 Stock Option (right to buy)

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Cuong V Do (President & CEO at BioVie Inc., BIVI) reported that they received 104,502 Stock Option (right to buy) on Dec 20, 2024.

Reporting person
Do Cuong V
Role
President & CEO

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Dec 20, 2024Grant or award (A)Stock Option (right to buy)On 104,502 Common Stock1, 2+104,502--104,502 indirect

Holdings before and after

  • Stock Option (right to buy): 0 to 104,502 indirect, See Footnote

Footnotes from the filing

  1. 1. The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.
  2. 2. Securities are held in the name of Do & Rickles Investments LLC.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Do report in this BIVI Form 4?

Cuong V Do (President & CEO at BioVie Inc., BIVI) reported that they received 104,502 Stock Option (right to buy) on Dec 20, 2024.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for BIVI

Earlier insider filings at BIVI

Quantisnow market dataNASDAQ
BioVie Inc. logo
BIVI
BioVie Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for BIVI

Follow BIVI and get a push notification the moment its next story breaks.

Full BIVI profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIVI (BioVie Inc.) and more on Quantisnow.